Literature DB >> 2818017

Systemic lupus erythematosus. III. Observations on clinical renal involvement and follow up of renal function: Dutch experience with 110 patients studied prospectively.

J C Nossent1, W Bronsveld, A J Swaak.   

Abstract

A prospective study of 110 patients with systemic lupus erythematosus (SLE) was undertaken to evaluate the reliability of clinical signs of lupus nephritis, which developed in 39 (35%) patients. Those patients with SLE who showed no clinical signs of lupus nephritis had an excellent survival rate (10 year survival 93%) and retained normal renal function (serum creatinine less than 130 mumols/l); clinical lupus nephritis developed mainly in the first three years after diagnosis of SLE and was associated with a decreased survival rate (10 year survival 62%). Increased mortality was found in male patients with lupus nephritis over 25 years of age and in female patients with lupus nephritis under 25 years of age, while renal failure rates did not differ between these groups. Treatment of lupus nephritis with high dose prednisone alone or in combination with immunosuppressants did not result in differences in patient survival or renal function preservation. It was concluded that clinical variables are a reliable guide in the management of patients with SLE, and routine use of renal biopsy in these patients is rejected.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2818017      PMCID: PMC1003886          DOI: 10.1136/ard.48.10.810

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

1.  Lupus nephropathy without clinical renal involvement.

Authors:  S K Mahajan; N G Ordóñez; P J Feitelson; V S Lim; B H Spargo; A I Katz
Journal:  Medicine (Baltimore)       Date:  1977-11       Impact factor: 1.889

2.  The prognosis of lupus nephritis. Role of clinical-pathologic correlations.

Authors:  B Zweiman; J Kornblum; J Cornog; E A Hildreth
Journal:  Ann Intern Med       Date:  1968-09       Impact factor: 25.391

3.  A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death.

Authors:  S Rosner; E M Ginzler; H S Diamond; M Weiner; M Schlesinger; J F Fries; C Wasner; T A Medsger; G Ziegler; J H Klippel; N M Hadler; D A Albert; E V Hess; G Spencer-Green; A Grayzel; D Worth; B H Hahn; E V Barnett
Journal:  Arthritis Rheum       Date:  1982-06

4.  The value of the renal biopsy in lupus nephritis.

Authors:  R T McCluskey
Journal:  Arthritis Rheum       Date:  1982-07

5.  "End-stage" lupus nephritis: clinical course to and outcome on dialysis. Experience with 39 patients.

Authors:  R P Kimberly; M D Lockshin; R L Sherman; J F Beary; J Mouradian; J S Cheigh
Journal:  Medicine (Baltimore)       Date:  1981-07       Impact factor: 1.889

6.  Mortality in lupus nephritis.

Authors:  J Karsh; J H Klippel; J E Balow; J L Decker
Journal:  Arthritis Rheum       Date:  1979-07

7.  Hypertension and renal disease in systemic lupus erythematosus.

Authors:  D R Budman; A D Steinberg
Journal:  Arch Intern Med       Date:  1976-09

8.  Renal damage in systemic lupus erythematosus with normal renal function.

Authors:  R M Hollcraft; E L Dubois; G D Lundberg; S B Chandor; S B Gilbert; F P Quismorio; B H Barbour; G J Friou
Journal:  J Rheumatol       Date:  1976-09       Impact factor: 4.666

9.  Marginal benefit of renal biopsy in systemic lupus erythematosus.

Authors:  J F Fries; J Porta; M H Liang
Journal:  Arch Intern Med       Date:  1978-09

10.  Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980.

Authors:  D J Wallace; T E Podell; J M Weiner; M B Cox; J R Klinenberg; S Forouzesh; E L Dubois
Journal:  Am J Med       Date:  1982-02       Impact factor: 4.965

View more
  8 in total

Review 1.  Combination treatment in autoimmune diseases: systemic lupus erythematosus.

Authors:  G Moroni; O Della Casa Alberighi; C Ponticelli
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Acquired loss of renal nuclease activity is restricted to DNaseI and is an organ-selective feature in murine lupus nephritis.

Authors:  Natalya Seredkina; Ole P Rekvig
Journal:  Am J Pathol       Date:  2011-06-30       Impact factor: 4.307

3.  The significance of arterial hypertension at the onset of clinical lupus nephritis.

Authors:  I P Naiker; V Chrystal; I G Randeree; Y K Seedat
Journal:  Postgrad Med J       Date:  1997-04       Impact factor: 2.401

4.  Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients.

Authors:  Yong Dai; Weiguo Sui; Huijuan Lan; Qiang Yan; He Huang; YuanShuai Huang
Journal:  Rheumatol Int       Date:  2008-11-08       Impact factor: 2.631

5.  Identification of unique microRNA signature associated with lupus nephritis.

Authors:  Jeannie L Te; Igor M Dozmorov; Joel M Guthridge; Kim L Nguyen; Joshua W Cavett; Jennifer A Kelly; Gail R Bruner; John B Harley; Joshua O Ojwang
Journal:  PLoS One       Date:  2010-05-11       Impact factor: 3.240

Review 6.  Treatment of systemic lupus erythematosus: which options do we have for therapy regimens?

Authors:  L Kater; R H Derksen; R J Hené
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

7.  Environmental factors predicting nephritis in systemic lupus erythematosus.

Authors:  T McAlindon; L Giannotta; N Taub; D D'Cruz; G Hughes
Journal:  Ann Rheum Dis       Date:  1993-10       Impact factor: 19.103

8.  Systemic lupus erythematosus on the Caribbean island of Curaçao: an epidemiological investigation.

Authors:  J C Nossent
Journal:  Ann Rheum Dis       Date:  1992-11       Impact factor: 19.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.